The Analyst Verdict: Mersana Therapeutics In The Eyes Of 5 Experts
The Analyst Verdict: Mersana Therapeutics In The Eyes Of 5 Experts
分析师的判决：5位专家眼中的Mersana疗法
5 analysts have shared their evaluations of Mersana Therapeutics (NASDAQ:MRSN) during the recent three months, expressing a mix of bullish and bearish perspectives.
在过去的三个月中，有5位分析师分享了他们对Mersana Therapeutics（纳斯达克股票代码：MRSN）的评估，他们表达了看涨和看跌的观点。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
下表概述了他们最近的评级，简要介绍了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $6.6, a high estimate of $9.00, and a low estimate of $5.00. Witnessing a positive shift, the current average has risen by 65.0% from the previous average price target of $4.00.
分析师通过对12个月目标股价的评估提供了更深入的见解，显示平均目标价为6.6美元，最高估计为9.00美元，低估值为5.00美元。当前的平均价格从之前的平均目标价4.00美元上涨了65.0％，出现了积极的变化。
Analyzing Analyst Ratings: A Detailed Breakdown
分析分析师评级：详细明细
The analysis of recent...
对分析师...
登录免费看全文
登录/注册